Investing.com - Actinium Pharmaceuticals (NYSE:ATNM) reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Actinium Pharmaceuticals announced earnings per share of $-0.380 on revenue of $45.00K. Analysts polled by Investing.com anticipated EPS of $-0.345 on revenue of $580K.
Actinium Pharmaceuticals shares are up 98.5% from the beginning of the year, still down 21.10% from its 52 week high of $15.12 set on November 3.
Actinium Pharmaceuticals follows other major Healthcare sector earnings this month
Actinium Pharmaceuticals's report follows an earnings beat by Eli Lilly on November 1, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
AbbVie had beat expectations on October 28 with third quarter EPS of $3.66 on revenue of $14.81B, compared to forecast for EPS of $3.58 on revenue of $14.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar